A Study Of The Safety And Efficacy Of Levetiracetam (Keppra®) (Ucb L059) In Children With Epilepsy
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00150709|
Recruitment Status : Completed
First Posted : September 8, 2005
Last Update Posted : February 15, 2017
|Condition or disease||Intervention/treatment||Phase|
|Epilepsy, Partial||Drug: Levetiracetam (Keppra)||Phase 3|
|Study Type :||Interventional (Clinical Trial)|
|Estimated Enrollment :||238 participants|
|Intervention Model:||Single Group Assignment|
|Masking:||None (Open Label)|
|Official Title:||A Multi-Center, Open-Label, Long-Term, Follow-Up Study Of The Safety And Efficacy Of Levetiracetam (Ucb L059) In Children With Epilepsy|
|Study Start Date :||February 1998|
|Primary Completion Date :||January 2006|
|Study Completion Date :||January 2006|
- To allow pediatric patients who have participated in a previous trials the opportunity to receive open-label levetiracetam (Keppra) treatment.
- Efficacy measured by weekly seizure frequency.
- To obtain standardized descriptive safety and efficacy data in pediatric epileptic patients
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00150709
|Study Director:||UCB Clinical Trial Call Center||UCB Pharma|